Literature DB >> 23447580

Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis.

Leiping Fu1, Gang Wang, Maria M Shevchuk, David M Nanus, Lorraine J Gudas.   

Abstract

Renal cell carcinoma (RCC) is the most common primary cancer arising from the kidney in adults, with clear cell renal cell carcinoma (ccRCC) representing approximately 75% of all RCCs. Increased expression of the hypoxia-induced factors-1α (HIF1α) and HIF2α has been suggested as a pivotal step in ccRCC carcinogenesis, but this has not been thoroughly tested. Here, we report that expression of a constitutively activated form of HIF2α (P405A, P530A, and N851A, named as HIF2αM3) in the proximal tubules of mice is not sufficient to promote ccRCC by itself, nor does it enhance HIF1αM3 oncogenesis when coexpressed with constitutively active HIF1αM3. Neoplastic transformation in kidneys was not detected at up to 33 months of age, nor was increased expression of Ki67 (MKI67), γH2AX (H2AFX), or CD70 observed. Furthermore, the genome-wide transcriptome of the transgenic kidneys does not resemble human ccRCC. We conclude that a constitutively active HIF2α is not sufficient to cause neoplastic transformation of proximal tubules, arguing against the idea that HIF2α activation is critical for ccRCC tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23447580      PMCID: PMC3642229          DOI: 10.1158/0008-5472.CAN-12-3983

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.

Authors:  M S Wiesener; P M Münchenhagen; I Berger; N V Morgan; J Roigas; A Schwiertz; J S Jürgensen; G Gruber; P H Maxwell; S A Löning; U Frei; E R Maher; H J Gröne; K U Eckardt
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

2.  Oct-3/4 is a dose-dependent oncogenic fate determinant.

Authors:  Sharon Gidekel; Galina Pizov; Yehudit Bergman; Eli Pikarsky
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

3.  CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC.

Authors:  Swethajit Biswas; Philip J S Charlesworth; Gareth D H Turner; Russell Leek; Paul T Thamboo; Leticia Campo; Helen Turley; Petra Dildey; Andrew Protheroe; David Cranston; Kevin C Gatter; Francesco Pezzella; Adrian L Harris
Journal:  Carcinogenesis       Date:  2012-07-09       Impact factor: 4.944

4.  HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.

Authors:  Stefano J Mandriota; Kevin J Turner; David R Davies; Paul G Murray; Neil V Morgan; Heidi M Sowter; Charles C Wykoff; Eamonn R Maher; Adrian L Harris; Peter J Ratcliffe; Patrick H Maxwell
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

5.  Preclinical characterization of SGN-70, a humanized antibody directed against CD70.

Authors:  Julie A McEarchern; Leia M Smith; Charlotte F McDonagh; Kerry Klussman; Kristine A Gordon; Carol A Morris-Tilden; Steven Duniho; Maureen Ryan; Tamar E Boursalian; Paul J Carter; Iqbal S Grewal; Che-Leung Law
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

6.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.

Authors:  John D Gordan; Priti Lal; Vijay R Dondeti; Richard Letrero; Krishna N Parekh; C Elisa Oquendo; Roger A Greenberg; Keith T Flaherty; W Kimryn Rathmell; Brian Keith; M Celeste Simon; Katherine L Nathanson
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

7.  Pattern of expression of gamma-glutamyl transpeptidase in rat liver and kidney during development: study by immunochemistry and in situ hybridization.

Authors:  E Jacquemin; F Bulle; J F Bernaudin; M Wellman; R N Hugon; G Guellaen; M Hadchouel
Journal:  J Pediatr Gastroenterol Nutr       Date:  1990-07       Impact factor: 2.839

8.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

Authors:  Michael Zimmer; Darrell Doucette; Naila Siddiqui; Othon Iliopoulos
Journal:  Mol Cancer Res       Date:  2004-02       Impact factor: 5.852

9.  High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas.

Authors:  Maria V Yusenko; Roland P Kuiper; Tamas Boethe; Börje Ljungberg; Ad Geurts van Kessel; Gyula Kovacs
Journal:  BMC Cancer       Date:  2009-05-18       Impact factor: 4.430

Review 10.  Biology of hypoxia-inducible factor-2alpha in development and disease.

Authors:  S A Patel; M C Simon
Journal:  Cell Death Differ       Date:  2008-02-15       Impact factor: 15.828

View more
  21 in total

1.  Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma.

Authors:  Denise R Minton; Leiping Fu; Nigel P Mongan; Maria M Shevchuk; David M Nanus; Lorraine J Gudas
Journal:  Clin Cancer Res       Date:  2016-01-18       Impact factor: 12.531

Review 2.  The HIF and other quandaries in VHL disease.

Authors:  D Tarade; M Ohh
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

3.  Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome.

Authors:  Leiping Fu; Denise R Minton; Tuo Zhang; David M Nanus; Lorraine J Gudas
Journal:  Mol Cancer Res       Date:  2015-02-25       Impact factor: 5.852

4.  Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR).

Authors:  Johannes C van der Mijn; Qiuying Chen; Kristian B Laursen; Francesca Khani; Xiaofei Wang; Princesca Dorsaint; Andrea Sboner; Steven S Gross; David M Nanus; Lorraine J Gudas
Journal:  Mol Carcinog       Date:  2022-06-21       Impact factor: 5.139

Review 5.  Blocking peptides and molecular mimicry as treatment for kidney disease.

Authors:  Andrea Havasi; Weining Lu; Herbert T Cohen; Laurence Beck; Zhiyong Wang; Chinaemare Igwebuike; Steven C Borkan
Journal:  Am J Physiol Renal Physiol       Date:  2016-09-21

Review 6.  Molecular targets on the horizon for kidney and urothelial cancer.

Authors:  Joaquim Bellmunt; Bin T Teh; Giampaolo Tortora; Jonathan E Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2013-08-27       Impact factor: 66.675

Review 7.  The role of HIF1α in renal cell carcinoma tumorigenesis.

Authors:  Lorraine J Gudas; Leiping Fu; Denise R Minton; Nigel P Mongan; David M Nanus
Journal:  J Mol Med (Berl)       Date:  2014-06-12       Impact factor: 4.599

Review 8.  VHL, the story of a tumour suppressor gene.

Authors:  Lucy Gossage; Tim Eisen; Eamonn R Maher
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

Review 9.  Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.

Authors:  Eric Jonasch; Cheryl Lyn Walker; W Kimryn Rathmell
Journal:  Nat Rev Nephrol       Date:  2020-11-03       Impact factor: 28.314

Review 10.  Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma.

Authors:  James J Hsieh; Valerie H Le; Toshinao Oyama; Christopher J Ricketts; Thai Huu Ho; Emily H Cheng
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.